Skip to content

Inspection Record

Guangxi Yulin Pharmaceutical Group Co. Ltd. — FDA 483 Findings

US FDAInspected 2025-03-21Published 2026-11-13 6 findingsEquipment and facilityStability and storageLaboratory and QC controlsProcess validationLabeling and packaging

View the regulator's official source The source document is always the basis for judgement.

Findings

1Equipment and facility

Equipment and utensils are not cleaned at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality, or purity of the drug product.

2Stability and storage

There is no written testing program designed to assess the stability characteristics of drug products.

3Laboratory and QC controls

Laboratory controls do not include the establishment ofscientifically sound and appropriate specifications, standards, and test procedures designed to assure that components and drug products conform to appropriate standards of identity, strength, quality and purity.

4Process validation

Written production and process control procedures are not followed in the execution of production and process control functions and documented at the time of performance.

5Laboratory and QC controls

Testing and release ofdrug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the identity and strength of each active ingredient prior to release.

6Labeling and packaging

Strict control is not exercised over labeling issued for use in drug product labeling operations.

Similar findings at other companies

GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.

A record as of the US FDA document published on 2026-11-13. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

Other records for this company

Guangxi Yulin Pharmaceutical Group Co. Ltd. findings history — including this company's other documentsAll US FDA findings US FDA documents, 2026 Go to Findings search
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.